Cara Therapeutic Stock Today
| CARA Stock | USD 0.31 0.01 3.33% |
Performance0 of 100
| Odds Of DistressOver 56
|
Cara Therapeutic is trading at 0.31 as of the 24th of November 2024, a 3.33 percent increase since the beginning of the trading day. The stock's open price was 0.3. Cara Therapeutic has over 56 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Cara Therapeutic are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of October 2024 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of January 2014 | Category Healthcare | Classification Health Care |
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. The company has 54.86 M outstanding shares of which 942.53 K shares are currently shorted by private and institutional investors with about 2.2 trading days to cover. More on Cara Therapeutic
Moving against Cara Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cara Stock Highlights
| CEO President | Christopher Posner | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Marijuana (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Cara Operations Limited | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, OBX Health Care, Oslo All Share, NASDAQ Health Care, NASDAQ Composite Total, Marijuana, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCara Therapeutic can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cara Therapeutic's financial leverage. It provides some insight into what part of Cara Therapeutic's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cara Therapeutic (CARA) is traded on NASDAQ Exchange in USA. It is located in 400 Atlantic Street, Stamford, CT, United States, 06901 and employs 55 people. Cara Therapeutic is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.74 M. Cara Therapeutic conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 54.86 M outstanding shares of which 942.53 K shares are currently shorted by private and institutional investors with about 2.2 trading days to cover.
Cara Therapeutic currently holds about 157.51 M in cash with (92.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cara Therapeutic Probability Of Bankruptcy
Ownership AllocationCara Therapeutic holds a total of 54.86 Million outstanding shares. Cara Therapeutic shows significant amount of outstanding shares owned by insiders and institutional investors . Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cara Ownership Details
Cara Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Stifel Financial Corp | 2024-06-30 | 443.2 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 389.7 K | |
| Jane Street Group Llc | 2024-06-30 | 376.5 K | |
| Two Sigma Investments Llc | 2024-09-30 | 240.9 K | |
| Fmr Inc | 2024-09-30 | 210.3 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 185.8 K | |
| State Street Corp | 2024-06-30 | 180.8 K | |
| Hrt Financial Llc | 2024-06-30 | 163.7 K | |
| Adar1 Capital Management Llc | 2024-09-30 | 159.5 K | |
| Vanguard Group Inc | 2024-09-30 | 2.2 M | |
| Chescapmanager Llc | 2024-09-30 | 1.7 M |
Cara Therapeutic Historical Income Statement
Cara Stock Against Markets
Cara Therapeutic Corporate Management
| Joana Goncalves | Chief Medical Officer | Profile | |
| Beth Weinberg | VP QA | Profile | |
| Joana MD | Chief Officer | Profile | |
| Eric Vandal | Senior Commercial | Profile | |
| Frdrique Menzaghi | Chief RD | Profile | |
| Iris Francesconi | Chief Relations | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cara Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.75) | Revenue Per Share 0.202 | Quarterly Revenue Growth (0.86) | Return On Assets (0.63) | Return On Equity (1.84) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.